Fig. 3From: Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug reviewNumber of CDR submissions for drugs for rare diseases by the number of clinical studies considered in each submission. Numbers above columns indicate the number of submissionsBack to article page